Fast and sharp decrease in calprotectin predicts remission by infliximab in anti-TNF naïve patients with ulcerative colitis
Authors:
- M. De VosMVM. De Vos
- O. DewitODO. Dewit
- G. D'HAensGDG. D'HAens
- F. BaertFBF. Baert
- F. FontaineFFF. Fontaine
- S. VermeireSVS. Vermeire
- D. FranchimontDFD. Franchimont
- T. MoreelsTMT. Moreels
- D. StaessenDSD. Staessen
- L. TerriereLTL. Terriere
- B. Vander CruyssenBCB. Vander Cruyssen
- E. LouisELE. Louis
- 1 June 2012
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 6 (5) , 557-562
Abstract
To evaluate the effect of infliximab induction therapy on calprotectin levels in patients with ulcerative colitis (UC). In this prospective study 53 patients with active UC from 17 centers were treated with infliximab therapy (5 mg/kg) at baseline, week 2, and week 6. Faecal calprotectin was measured every week. Sigmoidoscopies were performed at baseline, week 6 and week 10. Median calprotectin levels decreased from 1260 (IQR 278.5- 3418) at baseline to 72.5 (IQR 18.5 - 463) at week 10 (p<0.001). After 10 weeks, infliximab therapy induced endoscopic remission and a decrease in calprotectin to<50 mg/kg or at least a 80% decrease from baseline level in 58% of patients. A significant and steep decrease of calprotectin levels was seen at week 2 for patients with an endoscopic remission at week 10 as compared to patients who did not show a remission. (p<0.001). At week 10 an excellent correlation was found between endoscopic remission and clinical Mayo score reflected by an AUC of ROC analyses of 0.94 (0.87-1) and with calprotectin measurements (AUC 0.91 (0.81-1)) : all patients with calprotectin levels <50 mg/kg, and a normal clinical Mayo score (=0) were in endoscopic remission. Infliximab induces a fast and significant decrease of faecal calprotectin levels in anti-TNF naïve patients with ulcerative colitis predictive for remission of disease.Keywords
This publication has 13 references indexed in Scilit:
- Faecal calprotectin, lactoferrin, M2-pyruvate kinase and S100A12 in severe ulcerative colitis: a prospective multicentre comparison of predicting outcomes and monitoring responseGut, 2010
- Mucosal healing and steroid-sparing associated with infliximab for steroid-dependent ulcerative colitisJournal of Crohn's and Colitis, 2009
- Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapseInflammatory Bowel Diseases, 2009
- Fecal Calprotectin Predicts the Clinical Course of Acute Severe Ulcerative ColitisAmerican Journal of Gastroenterology, 2009
- Can Calprotectin Predict Relapse Risk in Inflammatory Bowel Disease?American Journal of Gastroenterology, 2008
- Accuracy of Four Fecal Assays in the Diagnosis of ColitisDiseases of the Colon & Rectum, 2007
- Infliximab for Induction and Maintenance Therapy for Ulcerative ColitisNew England Journal of Medicine, 2005
- Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn’s diseaseGut, 2005
- A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's DiseaseNew England Journal of Medicine, 1997
- Assessment of Disease Activity in Ulcerative Colitis by Faecal Calprotectin, a Novel Granulocyte Marker ProteinDigestion, 1997